Development of Exclusive and Efficient Intranasal or Pulmonary Dosing Methods for a Dry Powder Tuberculosis Vaccine for Use in Nonhuman Primates
Pulmonary and intranasal spray-dried ID93 + GLA-SE powders were successfully manufactured. The proposed dosing systems are expected to achieve exclusive pulmonary or intranasal delivery to nonhuman primates while requiring only a moderate amount of powder.
Authors
- Philip J. Kuehl (ORCID: https://orcid.org/0000-0002-7567-3002)
- Wynton D. McClary (ORCID: https://orcid.org/0000-0003-3210-4747)
- Maximilian Aisenstat
- Christopher B. Fox (ORCID: https://orcid.org/0000-0002-4644-2619)
- Reinhard Vehring (ORCID: https://orcid.org/0000-0002-4446-9826)
- Alana Gerhardt (ORCID: https://orcid.org/0000-0001-6753-7134)
- Joseph McCollum (ORCID: https://orcid.org/0000-0002-8104-4755)
- Andrew R. Martin (ORCID: https://orcid.org/0000-0002-3661-7016)
- Scott Tavernini (ORCID: https://orcid.org/0000-0003-3951-9339)
- Hui Wang (ORCID: https://orcid.org/0000-0002-1119-5849)
- Kelvin Duong
- J Chen (ORCID: https://orcid.org/0009-0006-7551-7874)
Institutions
- Utah State University (US)
- Lovelace Respiratory Research Institute (US)
- Infectious Disease Research Institute (US)
- University of Alberta (CA)
- Biomedical Research Institute (US)
Publication Details
- Journal
- Journal of Aerosol Medicine and Pulmonary Drug Delivery
- Published
- 2025-09-30
- DOI
- https://doi.org/10.1177/19412711251383716
- Primary Topic
- Inhalation and Respiratory Drug Delivery
- Type
- article
- Field-Weighted Citation Impact
- 0.00